BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D. Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry: Geographic Variations in CF. Pediatr Pulmonol 2015;50:754-62. [DOI: 10.1002/ppul.23185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Ramsay KA, Stockwell RE, Bell SC, Kidd TJ. Infection in cystic fibrosis: impact of the environment and climate. Expert Rev Respir Med 2016;10:505-19. [PMID: 26949990 DOI: 10.1586/17476348.2016.1162715] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Savant AP, McColley SA. Pediatric Pulmonology year in review 2015: Part 4. Pediatr Pulmonol 2016;51:754-65. [PMID: 27171478 DOI: 10.1002/ppul.23470] [Reference Citation Analysis]
3 Mohseni M, Razzaghmanesh M, Parsi Mehr E, Zare H, Beheshtian M, Najmabadi H. Novel CFTR Mutations in Two Iranian Families with Severe Cystic Fibrosis. Iran Biomed J 2016;20:201-6. [PMID: 27017198 DOI: 10.7508/ibj.2016.04.003] [Reference Citation Analysis]
4 Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D Jr. The Geographic Impact on Hospitalization in Patients with Cystic Fibrosis. J Pediatr 2016;170:246-52.e1-4. [PMID: 26690850 DOI: 10.1016/j.jpeds.2015.11.012] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Kopp BT, Hayes D, Ghera P, Patel A, Kirkby S, Kowatch RA, Splaingard M. Pilot trial of light therapy for depression in hospitalized patients with cystic fibrosis. Journal of Affective Disorders 2016;189:164-8. [DOI: 10.1016/j.jad.2015.08.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Oates G, Rutland S, Juarez L, Friedman A, Schechter MS. The association of area deprivation and state child health with respiratory outcomes of pediatric patients with cystic fibrosis in the United States. Pediatr Pulmonol 2021;56:883-90. [PMID: 33258546 DOI: 10.1002/ppul.25192] [Reference Citation Analysis]
7 Xie Y, Huang X, Liang Y, Xu L, Pei Y, Cheng Y, Zhang L, Tang W. A new compound heterozygous CFTR mutation in a Chinese family with cystic fibrosis. Clin Respir J. 2017;11:696-702. [PMID: 26471113 DOI: 10.1111/crj.12401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
8 Conrad DJ, Billings J, Teneback C, Koff J, Rosenbluth D, Bailey BA, Jain R. Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients. J Cyst Fibros 2021;20:91-6. [PMID: 32948498 DOI: 10.1016/j.jcf.2020.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Oates GR, Harris WT, Rowe SM, Solomon GM, Dey S, Zhu A, Hoover WC, Gutierrez HH. Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic Fibrosis. Pediatr Infect Dis J 2019;38:e285-9. [PMID: 31568067 DOI: 10.1097/INF.0000000000002419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
10 Hoch H, Sontag MK, Scarbro S, Juarez-colunga E, Mclean C, Kempe A, Sagel SD. Clinical outcomes in U.S. infants with cystic fibrosis from 2001 to 2012. Pediatr Pulmonol 2018;53:1492-7. [DOI: 10.1002/ppul.24165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
11 Waldhausen JHT, Richards M. Meconium Ileus. Clin Colon Rectal Surg 2018;31:121-6. [PMID: 29487495 DOI: 10.1055/s-0037-1609027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Villaverde-Hueso A, Sánchez-Díaz G, Molina-Cabrero FJ, Gallego E, Posada de la Paz M, Alonso-Ferreira V. Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations. Int J Environ Res Public Health 2019;16:E119. [PMID: 30621191 DOI: 10.3390/ijerph16010119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Psoter KJ, DE Roos AJ, Wakefield J, Mayer JD, Bryan M, Rosenfeld M. Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Epidemiol Infect 2016;144:1075-83. [PMID: 26449886 DOI: 10.1017/S0950268815002411] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
14 Singh SB, McLearn-Montz AJ, Milavetz F, Gates LK, Fox C, Murry LT, Sabus A, Porterfield HS, Fischer AJ. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol 2019;54:1200-8. [PMID: 31012285 DOI: 10.1002/ppul.24341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Muhlebach MS. Methicillin-resistant Staphylococcus aureus in cystic fibrosis: how should it be managed? Current Opinion in Pulmonary Medicine 2017;23:544-50. [DOI: 10.1097/mcp.0000000000000422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
16 Muhlebach MS, Jiang X, Kosorok MR, Klein EY, Saiman L. Longitudinal changes and regional variation of incident infection rates at cystic fibrosis centers, United States 2010-2016. J Cyst Fibros 2021:S1569-1993(21)01350-3. [PMID: 34456157 DOI: 10.1016/j.jcf.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]